Two liquid‑biopsy leaders sketched aggressive roadmaps for minimal residual disease (MRD) testing at JPM. Myriad told investors it will roll out tissue‑informed MRD assays across five tumor types over the next two years, starting with a breast cancer assay in early 2026 and broader commercial launches in 2027. Myriad also flagged AI‑enabled enhancements to its Prolaris prostate test and expanded hereditary cancer and prenatal portfolios. Natera, a rival in ctDNA MRD, reported record Signatera growth, previewed an assay upgrade that combines phased and structural variants to boost sensitivity, and expects expanded Medicare reimbursement to lift average selling prices. Both companies positioned MRD as a near‑term commercial growth engine and emphasized clinical studies to support coverage.